Soligenix Stock Price

0.00 (0.0%)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Soligenix Inc SNGX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.61 04:14:38
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
1.57 1.60 0.03 - -
Trades Volume Avg Volume 52 Week Range
2 70 3,916,574 1.21 - 3.68
Last Trade Time Type Quantity Stock Price Currency
04:02:15 65 $ 1.57 USD

Soligenix Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 50.69M 31.49M 31.38M $ 4.63M $ - -0.49 -2.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Soligenix News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SNGX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.83741.841.571.641,600,255-0.2274-12.38%
1 Month1.642.481.521.944,008,415-0.03-1.83%
3 Months2.422.801.211.714,180,959-0.81-33.47%
6 Months1.802.801.211.742,165,172-0.19-10.56%
1 Year3.033.681.211.841,625,195-1.42-46.86%
3 Years2.02023.700.651.79677,094-0.4102-20.3%
5 Years0.887.600.561.91469,3530.7382.95%

Soligenix Description

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.